In The Netherlands, Royal DSM purchased Amyris Brasil Ltda from Amyris, Inc. and established a long-term manufacturing partnership for Amyris’ high-volume products. Total consideration for Amyris Brasil Ltda, which owns and operates the Brotas 1 production facility, the intellectual property related to farnesene and an additional value share arrangement over a three-year period amounts to US$ 96 million.
With the acquisition of the Brotas 1 facility, DSM adds a state-of-the-art biotechnology-based production site in Brazil to its global network, with abundant availability of sustainable raw materials (sugar cane), securing production capacity for its rich pipeline of sustainable and bio-based solutions. Having broad experience in operating large-scale fermentation plants, DSM will optimize the operational performance of the site.
The sale of the Brotas 1 facility, which was designed to produce high volumes of farnesene, will enable Amyris to focus on its core strength of developing breakthrough bioscience technologies targeting key markets.